Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
64.37
-1.78 (-2.69%)
Official Closing Price
Updated: 7:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S Common Stock
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
81
82
Next >
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
October 07, 2024
Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects...
Via
Benzinga
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
October 06, 2024
Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have...
Via
Benzinga
Prediction: These 2 Stocks Will Join Nvidia, Meta, Apple, Amazon, and Microsoft in the Trillion-Dollar Club by 2030
October 06, 2024
These companies have been on fire for a while, but they haven't peaked yet.
Via
The Motley Fool
Novo
October 06, 2024
Check out this rather impressive head and shoulders pattern.The trend pre-dates the Congressional rebuke of its CEO.
Via
Talk Markets
Novo Nordisk's Options: A Look at What the Big Money is Thinking
October 04, 2024
Via
Benzinga
This Is What Whales Are Betting On Novo Nordisk
October 02, 2024
Via
Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,700 Today
September 27, 2024
Via
Benzinga
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
October 04, 2024
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over...
Via
Benzinga
Exposures
Product Safety
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
October 04, 2024
Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
October 04, 2024
NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss. Digital clinics and multidisciplinary teams will deliver the drug to...
Via
Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization...
Via
Benzinga
Exposures
Product Safety
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Via
Investor's Business Daily
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
October 03, 2024
Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to adverse effects, costs, and unmet expectations, raising concerns about...
Via
Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.
Via
Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
October 03, 2024
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli Lilly And Co's (NYSE:LLY) weight-loss and diabetes drugs from its shortage...
Via
Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
October 02, 2024
RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing growth opportunities in the U.S. Type 1 and Type 2 diabetes markets, product...
Via
Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
October 02, 2024
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.
Via
Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
October 02, 2024
Eli Lilly announces a $4.5B investment to build the Lilly Medicine Foundry, a state-of-the-art facility in Indiana. The new center will focus on advanced drug development and manufacturing, reinforcing...
Via
Benzinga
3 Momentum Trades Too Good Pass Up
October 02, 2024
Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.
Via
MarketBeat
Topics
ETFs
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
October 02, 2024
Eli Lilly is on track to become the first trillion-dollar pharma company, fueled by FDA-approved weight loss drugs. With a current valuation of $842 billion, analysts weigh investor risks as...
Via
Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
Via
Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
September 30, 2024
Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting...
Via
Benzinga
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
September 30, 2024
While growth is established for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), the stock's valuation remains reasonable.
Via
Chartmill
'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'
September 29, 2024
Via
Benzinga
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
September 28, 2024
These two players are set on finding the next big therapeutic modality.
Via
The Motley Fool
Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease
September 28, 2024
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. The Dow Jones Industrial Average hit a record high Friday as investors...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Latest Inflation Data Cements Fed's Interest Rate Call, S&P 500 Hits All-Time High, Biden Adviser Backs China EV Ban At Detroit Economic Club: This Week In The Markets
September 27, 2024
Inflation data supports another 0.5% interest rate cut in November, says RSM US LLP Chief Economist Joseph Brusuelas. S&P 500 hits all-time high. Brainard supports China EV ban. Meta Platforms unveils...
Via
Benzinga
Topics
Artificial Intelligence
Economy
Stocks
Exposures
Artificial Intelligence
Interest Rates
US Equities
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
81
82
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.